Picsum ID: 20
Isomorphic Labs, a startup spun out of DeepMind, is moving its artificial intelligence-designed drugs into human trials. The announcement was made by Isomorphic Labs president Max Jaderberg at WIRED Health in London.
Jaderberg stated that the company has developed a “broad and exciting pipeline of new medicines.” This development signifies a notable advancement in the application of AI to pharmaceutical research and drug development.